On January 8, Luye Pharmaceutical Group announced that the Drug Evaluation Center of the China National Drug Administration has officially accepted the marketing application for the new indications of the Group's Class 1 innovative drug Ruoxinlin®, which is intended to be used to treat generalized anxiety disorder.

Zhitongcaijing · 3d ago
On January 8, Luye Pharmaceutical Group announced that the Drug Evaluation Center of the China National Drug Administration has officially accepted the marketing application for the new indications of the Group's Class 1 innovative drug Ruoxinlin®, which is intended to be used to treat generalized anxiety disorder.